Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.contributor.author | 박경란 | * |
dc.date.accessioned | 2017-02-15T08:02:06Z | - |
dc.date.available | 2017-02-15T08:02:06Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1949-2553 | * |
dc.identifier.other | OAK-20094 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/234524 | - |
dc.description.abstract | Background and Purpose: This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy. Materials and Methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated. Results: Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2%. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with >= 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 Gy(EQD2)) was significantly associated with better DFS than the lower dose (<= 60.3 Gy(EQD2)). However, the radiation dose did not impact DFS in the low-risk group. Conclusions: Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 Gy(EQD2) were associated with better outcome in the high-risk patients. | * |
dc.language | English | * |
dc.publisher | IMPACT JOURNALS LLC | * |
dc.subject | breast neoplasms | * |
dc.subject | radiotherapy | * |
dc.subject | dose-response relationship | * |
dc.subject | prognosis | * |
dc.title | Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418) | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1796 | * |
dc.relation.lastpage | 1804 | * |
dc.relation.journaltitle | ONCOTARGET | * |
dc.identifier.doi | 10.18632/oncotarget.12882 | * |
dc.identifier.wosid | WOS:000391503300140 | * |
dc.identifier.scopusid | 2-s2.0-85009820816 | * |
dc.author.google | Kim, Haeyoung | * |
dc.author.google | Park, Won | * |
dc.author.google | Yu, Jeong Il | * |
dc.author.google | Choi, Doo Ho | * |
dc.author.google | Huh, Seung Jae | * |
dc.author.google | Kim, Yeon-Joo | * |
dc.author.google | Lee, Eun Sook | * |
dc.author.google | Lee, Keun Seok | * |
dc.author.google | Kang, Han-Sung | * |
dc.author.google | Park, In Hae | * |
dc.author.google | Shin, Kyung Hwan | * |
dc.author.google | Kim, Kyubo | * |
dc.author.google | Park, Kyung Ran | * |
dc.author.google | Kim, Yong Bae | * |
dc.author.google | Ahn, Sung Ja | * |
dc.author.google | Lee, Jong Hoon | * |
dc.author.google | Kim, Jin Hee | * |
dc.author.google | Chun, Mison | * |
dc.author.google | Lee, Hyung-Sik | * |
dc.author.google | Kim, Jung Soo | * |
dc.author.google | Lee, Jong-Young | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.contributor.scopusid | 박경란(14040340300;57203047823;57207108839;57308917900) | * |
dc.date.modifydate | 20240222162403 | * |